British Columbia Investment Management Corp increased its stake in Amgen Inc. (NASDAQ:AMGN) by 21.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 497,132 shares of the medical research company’s stock after buying an additional 88,989 shares during the period. British Columbia Investment Management Corp owned approximately 0.07% of Amgen worth $81,564,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of AMGN. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. First Command Financial Services Inc. increased its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the period. Cribstone Capital Management LLC increased its position in Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares during the period. Cable Hill Partners LLC increased its position in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock worth $161,000 after buying an additional 26 shares during the last quarter. Finally, Howe & Rusling Inc. increased its position in shares of Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock worth $485,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Amgen Inc. (AMGN) traded down 0.31% during midday trading on Friday, hitting $167.29. 1,741,936 shares of the company traded hands. The stock has a 50 day moving average price of $174.04 and a 200-day moving average price of $168.05. The company has a market cap of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the business earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. Analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 41.93%.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by BNB Daily and is owned by of BNB Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/amgen-inc-nasdaqamgn-shares-bought-by-british-columbia-investment-management-corp-updated-updated.html.
AMGN has been the subject of a number of analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $178.00 price target on shares of Amgen in a report on Tuesday, April 25th. Cowen and Company reissued a “buy” rating and issued a $209.00 price objective on shares of Amgen in a research report on Thursday, April 27th. Robert W. Baird reaffirmed a “neutral” rating and set a $165.00 target price on shares of Amgen in a research report on Friday, April 28th. Mizuho set a $195.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and an average price target of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is currently owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.